Keith Tapper
Stock Analyst at BMO Capital
(0.51)
# 3,896
Out of 4,761 analysts
5
Total ratings
40%
Success rate
-21.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $60 → $45 | $17.36 | +159.22% | 3 | Nov 20, 2024 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $1.61 | +210.56% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $19.95 | +55.39% | 1 | Jun 27, 2024 |
Neurogene
Nov 20, 2024
Maintains: Outperform
Price Target: $60 → $45
Current: $17.36
Upside: +159.22%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $1.61
Upside: +210.56%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $19.95
Upside: +55.39%